Increases in soluble tumor necrosis factor receptors coincide with increases in interleukin-6 and proteinases after major surgery

Hepato-Gastroenterology

Volumn 56, Issue 94-95, 2009, Pages 1377-1381

  Sasajima, Koji ^a   Futami, Ryouhei ^a   Matsutani, Takeshi ^a   Nomura, Tsutomu ^a   Makino, Hiroshi ^a   Maruyama, Hiroshi ^a   Miyashita, Masao ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cytokine; Elastase; Esophagectomy; Matrix metalloproteinase; Soluble receptor; Tumor necrosis factor alpha

Indexed keywords

ELASTASE; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; PROTEINASE; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 55; TUMOR NECROSIS FACTOR RECEPTOR 75; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; MAJOR SURGERY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 9; PANCREATIC ELASTASE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 71949131305     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. van der Poll T, Jansen J, van Leenen D, von der Mohlen M, Levi M, ten Cate H, et al: Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993;168:955-960. (Pubitemid 23282571)
2. Cinat ME, Waxman K, Granger GA, Pearce W, Annas C, Daughters K: Trauma causes sustained elevation of soluble tumor necrosis factor receptors. J Am Coll Surg 1994; 179:529-537.
3. Ertel W, Scholl FA, Gallati H, Bonaccio M, Shildberg F-W, Trentz O: Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis. Arch Surg 1994; 129:1330-1337.
4. Pilz G, Fraunberger P, Appel R, Kreuzer E, Werden K, Walli A, et al: Early prediction of outcome in score-identified, postoperative surgical patients at high risk for sepsis, using soluble tumor necrosis factor receptor-p55 concentrations. Crit Care Med 1996;24:596-600. (Pubitemid 26133792)
5. Rogy MA, Coyle SM, Oldenburg HAS, Rock CS, Barie PS, Van Zee KJ, et al: Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 1994; 178:132-138.
6. Sekinger P, Isaaz S, Dayer J-M: Purification and biologic characterization of a specific tumor necrosis factor a inhibitor. J Biol Chem 1989;264:11966-11973. (Pubitemid 19185370)
7. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D: A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989;264:11974-11980. (Pubitemid 19185371)
8. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-329.
9. Van Zee KJ, Kohno T, Fisher E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 1992;89:4845-4849.
10. Porteu F, Nathan C: Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990; 172:599-607. (Pubitemid 20248401)
11. Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan C: Human neutrophil elevates releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. J Biol Chem 1991; 266:18846-18853.
12. Crowe PD, Waltar BN, Mohler KM, Otten-Evans C, Black RA, Ware CF: A metalloproteinases inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995;181:1205-1210.
13. Peshon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, et al: An essential role for ectodomain shedding in mammalian development. Science 1998; 282:1281-1284.
14. Dekkers PEP, Lauw FN, ten Hove T, te Velde AA, Lumley P, Becherer D, et al: The effect of a metalloproteinase inhibitor (G15402) on tumor necrosis factor-α (TNF-α) and TNF-α receptors during human endotoxemia. Blood 1999; 94:2252-2258.
15. Owen CA, Campbell MA, Boukedes SS, Campbell EJ: Cytokines regulate membrane-bound leukocyte elastase on neutrophils: a novel mechanism for effector activity. Am J Physiol 1997;272:L385-393.
16. Klebanoff SJ, Vadas MA, Harlton FM, Sparks LH, Gamble JR, Agosti JM, et al: Stimulation of neutrophils by tumor necrosis factor. J Immunol 1986;136:4220-4225.
17. Johnson JL, Moore EE, Tamura DY, Zallen G, Biffl WL, Sillman CC: Interleukin-6 augments neutrophil cytotoxic potential via selective enhancement of elastase release. J Surg Res 1998;76:91-94. (Pubitemid 28363861)
18. Ertel W, Jarra D, Jochum M, Thiele V, Kenney J, Faist E, et al: Enhanced release of elastase is not concomitant with increased secretion of granulocyte-activating cytokines in whole blood from patients with sepsis. Arch Surg 1994;129:90-98. (Pubitemid 24024523)
19. Pugin J, Winder M-C, Kossodo S, Liang C-M, Preas HL II, Suffredini AF: Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatoy mediators. Am J Respir Cell Mol Biol 1999;20:458-464. (Pubitemid 129504868)
20. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA: Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990;75:40-47. (Pubitemid 20031487)
21. Ulich TR, Yin S, Guo K, Yi ES, Remik D, del Castillo J: Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am J Pathol 1991;138:1097-1101.
22. Tilz H, Trehu E, Atkins MB, Dinarello CA, Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113-118.
23. Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ: Systemic cytokine response after major surgery. Br J Surg 1992;79:757-760.
24. Naito Y, Tamai S, Shingu K, Shindo K, Matsui T, Segawa H, et al: Responses of plasma adrenocorticotropic hormone, cortisol, and cytokines during and after upper abdominal surgery. Anesthesiol 1992; 77:426-431.
25. Roumen RH, Hendriks T, van der Ven-Jongekrijg J, Nieuwenhuijzen GAP, Sauerwein RW, van der Meer JWM, et al: Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993; 218:769-776.
26. Matsutani T, Onda M, Sasajima K, Miyashita M: Glucocorticoid attenuates a decrease of antithrombin III following major surgery. J Surg Res 1998;79:158-163. (Pubitemid 28467352)
27. Kimura F, Miyazaki M, Suwa T, Sugiura T, Shinoda T, Itoh H, et al: Plasma concentration of cytokine antagonist in patients with infection following liver resection. Br J Surg 1998;85:1631-1635. (Pubitemid 28548337)
28. Shroder J, Gallati H, Kremer B: Increased serum levels of soluble tumor necrosis factor α-receptors in patients undergoing partial liver resection. Hepatogastroenterol 1998;45:1807-1812. (Pubitemid 28515206)
29. Krohn CD, Reikeras O, Aasen AO: The cytokines IL-1β and IL-1 receptor antagonist, IL-2 and IL-2 soluble receptor-α, IL-6 and IL-6 soluble receptor, TNF-α and TNF soluble receptor I, and IL10 in drained and systemic blood after major orthopaedic surgery. Eur J Surg 1999;165:101-109. (Pubitemid 29381743)
30. Borish L, Rosenbaum R, Albury L, Clark S: Activation of neutrophils by recombinant interleukin 6. Cell Immunol 1898;121:280-289.
31. Kossakowska AE, Edwards DR, Prusinkiewicz CP, Zhang M, Guo D, Urbanski SJ, et al: Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgikin's lymphomas. Blood 1999;94:2080-2089. (Pubitemid 29430425)
32. Duswald K-H, Jochum M, Schramm W, Friz H: Released granulocyte elastase: An indicator of pathobiochemical alterations in septicemia after abdominal surgery. Surgery 1985;98:892-899.
33. Nuijeins JH, Abbink JJ, Wachtfogel YT, Colman RW, Eerenberg AJM, Dors D, et al: Plasma elastase α1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med 1992;119:159-168.
34. Bjornberg F, Lantz M, Gullberg U: Metalloproteinases and serineproteases are involved in the cleavage of the two tumour necrosis factor (TNF) receptors to soluble forms in the myeloid cell lines U-937 and thp-1. Scand J Immunol 1995;42:418-424.
35. Zuker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, et al: Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci 1999;878:212-227. (Pubitemid 29353573)
36. Ricou B, Nicod L, Lacrez S, Welgus HG, Suter PM, Dayer J-M: Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;154:346-352. (Pubitemid 26269102)
37. Mautino G, Henriquest C, Jaffuel D, Bousquest J, Capony F: Tissue inhibitor of metalloproteinase-1 levels in bronchoalveolar lavage fluid from asthmatic subjects. Am J Respir Crit Care Med 1999; 160:324-330. (Pubitemid 29326107)
38. Pajulo OT, Pulkki KJ, Alanen MS, Reunanen MS, Lertola KK, Mattila-Vuori AI, et al: Correlation between interleukin-6 and matrix metalloproteinase-9 in early wound healing in children. Wound Repair Regen 1999;7:453-457.
39. Okawa K, Onda M, Miyashita M, Sasajima K: Systemic and pulmonary responses of inflammatory cytokines following esophagectomy. J Nippon Med Sch 1998;65:42-49.